Live·Open questions in longevity research
All news
Longevity researchClinical trialsIndustry & policy

Steve Horvath, one of the developers of DNA-based biological age tests known as “epigenetic clocks,” says a series of trials must establish whether turning back the clocks with a drug benefits health, while David Sinclair proposes standardizing the test and using it in those trials

18 November 2026· 261118006

Steve Horvath, one of the developers of DNA-based biological age tests known as “epigenetic clocks,” says a series of trials must establish whether turning back the clocks with a drug benefits health, while David Sinclair proposes standardizing the test and using it in those trials

In the November 16 episode of the Lifespan podcast, host Sinclair, a Harvard geneticist, talks with Horvath. The clocks estimate age from methylation, chemical marks on DNA, and, according to Horvath, predict the risk of death and disease.

Horvath asks:

“Suppose there is a drug that turns your epigenetic age back by ten years… Does that mean it benefits your health?”

Sinclair counters that prediction does not require reversing disease: a reliable, stable measure that offers a way to “look into the future” should help doctors. He cites LDL, the “bad” cholesterol, whose levels already predicted heart disease. Horvath uses the same example: LDL is a “validated surrogate endpoint,” a measure whose reduction can allow a regulator to approve a drug without waiting for heart attacks and deaths to occur. He says the clocks need “many clinical trials” to reach that point. Sinclair asks whether the LDL test came before the drugs. Yes, Horvath replies, but to accept the measure as validated, the FDA wanted to see that practically any intervention that lowered LDL reduced the risk of heart disease.

Sinclair believes the clocks are now at the same stage as LDL in the 1980s:

“That is why I am saying: let’s do this. Then we can use it as a tool for future clinical trials… We need a test for clinical trials.”

The link between LDL and heart attacks was identified back in the 1950s. In 1984, the Lipid Research Clinics trial showed that cholestyramine, a drug that lowers LDL, reduced the risk of dying from heart disease or having a heart attack by 19%. In 1987, the FDA approved another drug, lovastatin, the first statin, on the basis of LDL reduction, although evidence that a statin protected the heart was still lacking: that evidence came in 1994 from the 4S trial, in which the risk of death was 30% lower with simvastatin than with placebo.

Both support standardization: they want laboratories that measure methylation to agree on a common protocol. Sinclair suggests that Horvath lead the effort. “It is either me or the companies,” Horvath replies: gaining acceptance for the clocks, ideally from a regulator, requires funding. An LDL test in Boston gives results comparable to one in Los Angeles, he explains. A common protocol for the clocks is technically feasible, but someone needs to do the work.

Horvath says it is too early for doctors to order such a test: doctors order a test when they have a treatment to offer for an unfavorable result. Sinclair counters that doctors can recommend exercise and dietary changes, and Horvath agrees that some of these recommendations move the clocks in a favorable direction. None of the 26 studies in a review that measured both epigenetic clocks and health in humans provided the validation Horvath calls for: testing whether a change in the clocks predicts the health benefits of treatment across several independent trials.

Sinclair asks whether the clocks can run backward without any improvement in cell function. Horvath acknowledges that they can: treating cells in a dish with a substance that removes methylation throughout the genome makes the clocks indicate rejuvenation, but it is unclear whether the cells have been rejuvenated or the clocks themselves have been disrupted. According to Sinclair, OSK, a method that reprograms cells using three proteins, “really does turn the hands back, and that is connected to the mechanism,” whereas such a substance simply moves the hands without affecting the mechanism. “The clocks can be fooled. There is no question about that,” Horvath agrees.

Originally published on Telegram by Ukhvat NewsView on Telegram
Sources
#epigenetic-clocks#biological-age#dna-methylation#surrogate-endpoints#fda-validation#rejuvenation